Evidence map›Paper›PMID 38406513›Full record

ArticleEJHaem2024

A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease.

Myrthe J van Dijk, Marissa J M Traets, Brigitte A van Oirschot, Titine J J Ruiter, Jonathan R A de Wilde, Jennifer Bos, Wouter W van Solinge, Margaret J Koziel, Judith J M Jans, Revati Wani and 3 more

Open access · diamondAbstract read
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Myrthe J van DijkDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.ORCID https://orcid.org/0000-0002-9377-0367
Marissa J M TraetsDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.ORCID https://orcid.org/0000-0003-0821-7995
Brigitte A van OirschotDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Titine J J RuiterDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Jonathan R A de WildeDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Jennifer BosDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Wouter W van SolingeDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Margaret J KozielAxcella Therapeutics Cambridge Massachusetts USA.
Judith J M JansSection Metabolic Diagnostics, Department of Genetics University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Revati WaniAxcella Therapeutics Cambridge Massachusetts USA.
Eduard J van BeersCenter for Benign Hematology, Thrombosis and Hemostasis-Van Creveldkliniek University Medical Center Utrecht Utrecht University Utrecht The Netherlands.ORCID https://orcid.org/0000-0002-3934-7189
Richard van WijkDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.
Minke A E RabDepartment of Central Diagnostic Laboratory-Research, University Medical Center Utrecht Utrecht University Utrecht The Netherlands.ORCID https://orcid.org/0000-0002-8306-8726
Utrecht University · NLAxcella Health (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most common forms of sickle cell disease (SCD) are sickle cell anemia (SCA; HbSS) and HbSC disease. In both, especially the more dense, dehydrated and adherent red blood cells (RBCs) with reduced deformability are prone to hemolysis and sickling, and thereby vaso-occlusion. Based on plasma amino acid profiling in SCD, a composition of 10 amino acids and derivatives (RCitNacQCarLKHVS; Axcella Therapeutics, USA), referred to as endogenous metabolic modulators (EMMs), was designed to target RBC metabolism. The effects of ex vivo treatment with the EMM composition on different RBC properties were studied in SCD (

Indexed as

amino acidsanemiametabolismred blood cellsickle cell disease

Identifiers

PMID38406513
PMCPMC10887255
OpenAlexW4392183996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.